Loading...
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
DeFriend, D Robertson, J Blamey, R Walton, P
DeFriend, D
Robertson, J
Blamey, R
Walton, P
Citations
Altmetric:
Abstract
We treated 19 patients with advanced breast cancer resistant to tamoxifen with a new specific antioestrogen (ICI 182780) which, in animal studies, has no agonist activity. 13 (69%) patients responded (7 had partial responses and 6 showed no change) to monthly intramuscular injections of ICI 182780 after progression on tamoxifen, for a median duration of 18 months with minimum side effects. Preliminary evidence suggests that the agent is without effects on the liver or the hypothalamic-pituitary axis. ICI 182780 appears to be a promising new agent for treatment of advanced and early breast cancer.
Description
Date
1995-01-07
Publisher
Collections
Keywords
Breast Cancer
Oestrogen Antagonists
Oestrogen Antagonists
Type
Article
Citation
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. 1995, 345 (8941):29-30 Lancet